证券代码：600351 证券简称：亚宝药业 公告编号：2025-029 亚宝药业集团股份有限公司 关于签订中药新药项目技术转让协议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、交易概述 山西省中医院建院于 1957 年，是全国成立最早的中医药科研院所之一，是 集医疗、科研、教学、产业为一体的三级甲等中医医疗机构。1978 年入选全国 首批硕士学位授予单位，1999 年获批国家药品临床药理研究基地，2017 年获批 国家中医药传承创新工程建设单位，2018 年获批全国中医临床研究基地建设单 位，2022 年获批国家中医药传承创新中心建设单位和国家中医疫病基地，2023 年入选国家中医医疗队成员单位。山西省中医院设 6 个研究所和 12 个研究室， 有国家中医药管理局首批重点研究室（中医肠疗）1 个、重点学科 6 个、三级实 验室 3 个和清洁级实验动物室 1 个，国医大师、全国、省名中医工作室 61 个。 近年来共承担各级各类科研课题 1033 项，取得省级科技进步奖 120 项，省科技 进步一等奖 4 项、二等奖 ...

Core Viewpoint - The company has signed a technology transfer agreement for a new traditional Chinese medicine project, which is expected to enhance its R&D capabilities and competitiveness in the market [1] Group 1: Agreement Details - The company signed a technology transfer agreement with Shanxi Traditional Chinese Medicine Research Institute on August 4, 2025 [1] - The company acquired the clinical trial approval, patent rights, and related technical materials for the traditional Chinese medicine new drug "Chaiqin Ning Shen Granules" for RMB 22 million [1] Group 2: Strategic Implications - The acquisition of the clinical trial approval and patent rights is expected to facilitate the rapid expansion of the company's traditional Chinese medicine R&D pipeline [1] - This move aligns with the company's development strategy and is in the interest of all shareholders [1] Group 3: Impact on Financial Performance - The agreement's implementation timeline is lengthy, and it is noted that there will be no significant short-term impact on the company's operating performance [1]

Core Viewpoint - The company has signed a technology transfer agreement for a new traditional Chinese medicine, which is expected to enhance its R&D capabilities and competitiveness in the market [1] Group 1: Agreement Details - On August 4, 2025, the company signed a technology transfer agreement with Shanxi Traditional Chinese Medicine Research Institute [1] - The company acquired the clinical trial approval, patent rights, and related technical materials for the Class 1 new drug "Chaiqin Ning Shen Granules" for a total of 22 million RMB [1] - This transaction does not constitute a related party transaction and does not require approval from the board of directors or shareholders [1] Group 2: Strategic Implications - The acquisition is expected to facilitate the rapid expansion of the company's pipeline for innovative traditional Chinese medicine [1] - It aims to accelerate the development of new products, thereby enhancing the company's core competitiveness and sustainable development capabilities [1] - The transaction aligns with the company's development strategy and benefits all shareholders [1] Group 3: Financial Impact - The transaction is not expected to have a significant impact on the company's operating performance in the short term [1]

人民财讯8月5日电，亚宝药业(600351)8月5日晚间公告，公司于8月4日与山西省中医药研究院（简 称"山西省中医院"）签署了中药新药项目技术转让协议。公司以2200万元受让山西省中医院拥有的中药 1.1类新药"柴芩宁神颗粒"的临床试验批件、专利权及相关技术资料。 转自：证券时报 ...

格隆汇8月5日丨亚宝药业(600351.SH)公布，公司于2025年8月4日与山西省中医药研究院（称"山西省中 医院"）签署了中药新药项目技术转让协议（称"协议"）。公司以人民币2200万元受让山西省中医院拥 有的中药1.1类新药"柴芩宁神颗粒"的临床试验批件、专利权及相关技术资料。 ...

公司本次受让中药创新药柴芩宁神颗粒临床试验批件和发明专利等相关技术，有利于公司快速拓展公司 中药创新药研发管线，加快公司新产品研发进度，提高公司的核心竞争力和可持续发展能力，符合公司 的发展战略以及全体股东的利益。本次协议签订后，因各事项的推进时间较长,存在不确定性，短期内 不会对公司经营业绩产生重大影响。 亚宝药业（600351）(600351.SH)发布公告，公司于2025年8月4日与山西省中医药研究院(简称"山西省中 医院")签署了中药新药项目技术转让协议。公司以人民币2200万元受让山西省中医院拥有的中药1.1类 新药"柴芩宁神颗粒"的临床试验批件、专利权及相关技术资料。 ...

Group 1 - The company has approved a share repurchase plan at the 2024 annual general meeting, with a total repurchase fund of no less than RMB 50 million and no more than RMB 100 million, at a price not exceeding RMB 6.95 per share [1] - The repurchase period is set for a maximum of 6 months from the date of approval, with funds sourced from the company's own and raised funds [1] - As of July 31, 2025, the company has repurchased a total of 200,000 shares, accounting for 0.03% of the total share capital, with a total payment of RMB 1,260,000 at a maximum and minimum transaction price of RMB 6.30 per share [1] Group 2 - The company will adhere to relevant regulations during the repurchase period and will make repurchase decisions based on market conditions, ensuring timely information disclosure [2]

Group 1 - The core point of the article is that Yabao Pharmaceutical announced a share buyback program, having repurchased a total of 200,000 shares as of July 31, 2025, which represents 0.03% of the company's total share capital [2] Group 2 - The share repurchase was conducted through centralized bidding transactions [2] - The announcement was made on the evening of August 1 [2] - The buyback program is part of the company's strategy to enhance shareholder value [2]

亚宝药业集团股份有限公司 证券代码：600351 证券简称：亚宝药业 公告编号：2025-028 亚宝药业集团股份有限公司（以下简称"公司"）于 2025 年 5 月 16 日召开 了 2024 年年度股东大会，审议通过了《关于以集中竞价交易方式回购股份方案的 议案》，同意公司以集中竞价方式回购公司股份，回购股份的资金总额不低于人民 币 0.5 亿元（含）且不超过人民币 1 亿元（含），回购股份价格不超过人民币 6.95 元/股，回购用途为全部予以注销并减少公司注册资本，回购期限为自股东大会审 议通过回购方案之日起不超过 6 个月，本次回购资金来源为公司自有资金及自筹 资 金 。 具 体 内 容 详 见 公 司 于 2025 年 5 月 17 日 在 上 海 证 券 交 易 所 网 站 （www.sse.com.cn）及《中国证券报》《上海证券报》上发布的《亚宝药业集团股 份有限公司关于以集中竞价交易方式回购股份的回购报告书》（公告编号： 2025-020）。 二、回购股份的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，公司在回购期间应当在每个月 ...

Group 1 - The company, Yabao Pharmaceutical (600351.SH), announced that as of July 31, 2025, it has repurchased a total of 200,000 shares through centralized bidding, accounting for 0.03% of the company's total share capital [1] - The highest and lowest transaction price for the repurchased shares was 6.30 RMB per share, indicating a stable price point during the buyback [1] - The total amount paid for the share repurchase was 1.26 million RMB, excluding transaction fees, reflecting the company's commitment to returning value to shareholders [1]